Nilsson Johan B, Boman Kurt, Jansson Jan-Håkan, Nilsson Torbjörn, Näslund Ulf
Department of Cardiology, Heart Centre, University Hospital, Umea 901 85, Sweden.
J Thromb Thrombolysis. 2008 Dec;26(3):188-95. doi: 10.1007/s11239-007-0086-9. Epub 2007 Aug 25.
The fibrinolytic system and von Willebrand factor (vWF) have been shown to play a role as risk factors for myocardial infarction. We performed this prospective cohort study to determine if components in the fibrinolytic system or vWF before or during treatment of AMI with streptokinase (SK) could predict reperfusion, recurrent ischaemia, reinfarction or mortality at one year, or mortality at five years. Reperfusion and recurrent ischaemia were assessed by continuous vectorcardiography. The setting was Umeå university hospital and Skellefteå county hospital, Sweden.
139 patients were included; successful reperfusion was obtained in 53%. tPA activity, PAI-activity, PAI-mass concentration and vWF were analysed immediately on arrival and after 4 and 10 h. High fibrinolytic activity, measured as tPA activity > 25 U/L after the start of treatment, was associated with reperfusion. No significant associations between pre-treatment levels of the fibrinolytic variables or vWF and reperfusion or recurrent ischaemia were found. Elevated levels of PAI-1 mass concentration and PAI-1 activity after the start of SK treatment were associated with a higher risk for death at one year, but not at five years. High levels of vWF were associated with worse prognosis but not when corrected for age.
Pre-treatment levels of PAI-1, vWF and tPA activity showed no association with reperfusion or recurrent ischaemia. Elevated levels of PAI-1 activity after the start of treatment were associated with worse prognosis.
纤维蛋白溶解系统和血管性血友病因子(vWF)已被证明是心肌梗死的危险因素。我们进行了这项前瞻性队列研究,以确定在使用链激酶(SK)治疗急性心肌梗死(AMI)之前或期间,纤维蛋白溶解系统或vWF的成分是否能够预测一年后的再灌注、复发性缺血、再梗死或死亡率,以及五年后的死亡率。通过连续向量心电图评估再灌注和复发性缺血。研究地点为瑞典于默奥大学医院和谢莱夫特奥县医院。
纳入139例患者;53%获得成功再灌注。在患者到达时以及4小时和10小时后立即分析组织型纤溶酶原激活物(tPA)活性、纤溶酶原激活物抑制剂(PAI)活性、PAI质量浓度和vWF。以治疗开始后tPA活性>25 U/L衡量的高纤维蛋白溶解活性与再灌注相关。未发现纤维蛋白溶解变量或vWF的治疗前水平与再灌注或复发性缺血之间存在显著关联。SK治疗开始后PAI-1质量浓度和PAI-1活性升高与一年后死亡风险较高相关,但与五年后死亡风险无关。高水平的vWF与较差的预后相关,但校正年龄后则无此关联。
PAI-1、vWF和tPA活性的治疗前水平与再灌注或复发性缺血无关。治疗开始后PAI-1活性升高与较差的预后相关。